Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
A promising new drug for lung cancer is generating interest, but experts say the data need to catch up. Izalontamab brengitecan (iza-bren), a bispecific antibody-drug conjugate targeting both EGFR and HER3, is showing competitive response rates in pretreated NSCLC patients. However, where exactly it fits in the treatment lineup after osimertinib remains an open question amid a crowded field of competitors.
A new dual-targeting drug is drawing attention in lung cancer treatment, but oncologists are urging patience before defining its role. Izalontamab brengitecan (iza-bren), a bispecific antibody-drug conjugate (ADC) targeting both EGFR and HER3, has a rational scientific basis — HER3 expression is more common in EGFR-mutated lung cancers, making dual targeting a logical approach. Early data show competitive response rates and durable responses in pretreated patients, though cytopenias remain a notable side effect concern.
Big questions still linger. Most existing data come from China, and global trials are now underway to broaden the evidence base. The treatment landscape after osimertinib (Tagrisso) is increasingly crowded, with rivals like sacituzumab tirumotecan, ivonescimab plus chemotherapy (under FDA review with a target action date of November 14, 2026), and savolitinib for MET-driven disease all vying for position. Whether iza-bren lands in the second, third, or even first line remains unclear.
Key Takeaways:
Why it matters: As EGFR-mutated NSCLC treatment evolves into a multi-step patient journey, oncologists face mounting complexity in sequencing therapies. Iza-bren could become an important tool — but its ultimate place in the lineup will be decided by data, not enthusiasm.
